{"id":14780,"date":"2020-09-23T07:56:36","date_gmt":"2020-09-22T18:56:36","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=14780"},"modified":"2020-09-23T07:56:36","modified_gmt":"2020-09-22T18:56:36","slug":"triple-therapy-for-cll-shows-promise-in-phase-2-trial","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=14780","title":{"rendered":"Triple Therapy for CLL Shows Promise in Phase 2 Trial"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”50″ gutter_size=”3″ column_width_percent=”100″ shift_y=”0″ z_index=”0″][vc_column column_width_percent=”100″ gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ shift_y_down=”0″ z_index=”0″ medium_width=”0″ mobile_width=”0″ width=”1\/1″][vc_custom_heading heading_semantic=”h1″ text_size=”h1″]<\/p>\n

Triple Therapy for CLL Shows Promise in Phase 2 Trial<\/h1>\n

<\/h2>\n

[\/vc_custom_heading][vc_column_text]This article was originally published by Cancer Therapy Advisor\u00a0<\/a><\/p>\n

Results from a phase 2 study of 3 oral targeted agents for chronic lymphocytic leukemia (CLL) showed that patients achieved deep remissions after a limited-time duration treatment. The study, published in the\u00a0Journal of Clinical Oncology<\/em>, included both treatment-naive patients and those with recurrent\/relapsed disease.1<\/sup>\u00a0The regimen worked well enough that phase 3 studies are underway.<\/p>\n

Patients in this trial (ClinicalTrials.gov Identifier:\u00a0NCT02427451<\/a>) received a combination regimen of obinutuzumab, ibrutinib, and venetoclax.2<\/sup>\u00a0The 3 agents have different mechanisms of action, and are thought to combine well against CLL. Obinutuzumab, an anti-CD20 monoclonal antibody, is given first, followed by ibrutinib, which inhibits the B-cell signaling protein Bruton tyrosine kinase (BTK). Venetoclax, a BCL-2 inhibitor, comes last.<\/p>\n

\u201cWe took the 3 most highly effective nonchemotherapy drugs that we had in CLL, put them in this regimen, and dosed them so they\u2019re started sequentially,\u201d said the study\u2019s lead investigator Kerry Rogers, MD, hematologist with The Ohio State University Comprehensive Cancer Center\u2019s Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus.<\/p>\n

 <\/p>\n

To continue reading this article on Cancer Therapy Advisor<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Results from a phase 2 study of 3 oral targeted agents for chronic lymphocytic leukemia (CLL) showed that patients achieved deep remissions after a limited-time duration treatment. <\/p>\n","protected":false},"author":1,"featured_media":14781,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17,23],"tags":[],"class_list":["post-14780","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured","category-research"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2020\/09\/for-CLL.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14780"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14780\/revisions"}],"predecessor-version":[{"id":14782,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/14780\/revisions\/14782"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/14781"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}